Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

KPV Dosing Protocol: 10 mg Vial — Anti-Inflammatory & Gut Healing Guide

KPV (Lys-Pro-Val) tripeptide dosing protocol for subcutaneous and oral administration, targeting inflammatory bowel conditions, skin inflammation, and wound healing.

Go to peptide profileCalculate your dose

Quickstart highlights

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH).

  • Concentration: 2 mg/mL (10 mg vial + 5 mL bacteriostatic water).
  • At 2 mg/mL: 100 µg = 5 units, 250 µg = 12.5 units, 500 µg = 25 units.
  • Oral or subcutaneous delivery is both viable — KPV resists gastric acid degradation.
  • One 10 mg vial provides 40 doses at 250 µg — approximately 5–6 weeks at once-daily dosing.
  • Combine with BPC-157 for synergistic gut mucosal repair.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-41005Once or twice daily100 µg — 5 units; conservative start; 10 mg vial provides 100 doses at this level
5-1225012Once or twice daily250 µg — 12.5 units; standard therapeutic dose for IBD and wound healing
13+50025Once daily500 µg — 25 units; higher dose for severe inflammatory conditions or acute flares

Reconstitution steps

  1. Draw 5 mL bacteriostatic water (two 2.5 mL draws); inject slowly down the vial wall.
  2. Swirl gently until the tripeptide dissolves; do not shake.
  3. Final concentration: 2 mg/mL. At 2 mg/mL: 100 µg = 5 units, 250 µg = 12.5 units.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

8-week plan

  • 1 vial
  • 56 syringes
  • 5 mL bac water
  • 56 alcohol swabs

12-week plan

  • 1 vial
  • 84 syringes
  • 5 mL bac water
  • 84 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Reduce intestinal and systemic inflammation through KPV alpha-MSH tripeptide receptor activation, targeting NF-κB and STAT3 pathways with subcutaneous or oral delivery for inflammatory bowel disease, skin conditions, or wound healing.

Cycle length: 12 weeks on.

Off-cycle: 4 weeks off; reassess inflammatory markers before resuming.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 28 days. KPV is stable to oral administration — oral and SC routes are both validated in animal models.

Injection & tracking tips

  • For IBD and gut-targeted use: administer KPV orally (draw dose into syringe, add to water, swallow on empty stomach) — KPV's tripeptide structure resists gastric acid degradation.
  • For skin inflammation or wound healing: use subcutaneous injection near the inflammatory site.
  • KPV can be combined with BPC-157 for synergistic gut mucosal healing — complementary anti-inflammatory pathways.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • For IBD protocols: track daily stool frequency, blood in stool, and abdominal pain (0–10 Harvey-Bradshaw index) weekly.
  • For wound healing: photograph wound every 3 days and measure dimensions weekly.
  • Monitor CRP and calprotectin (if IBD) at baseline and 6 weeks.
Log your cycle in the calculator →

How this works & references

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH). It retains anti-inflammatory properties without the melanotropic side effects of the full peptide. KPV binds melanocortin receptors (MC1R and MC3R) and inhibits NF-κB nuclear translocation and STAT3 phosphorylation, reducing IL-1β, TNF-α, and IL-6 production. Dalmasso et al. (2008) demonstrated KPV-loaded nanoparticles reduced DSS-induced colitis severity in mice by 60–70%. Residue-specific resistance to peptidase degradation makes oral delivery viable.

Sources

Frequently asked questions

Is KPV better taken orally or by injection for IBD?
For IBD, oral administration (at least 250 µg daily on an empty stomach) may provide superior gut mucosal targeting compared to subcutaneous injection, as KPV passes through the intestinal lumen where it contacts inflamed epithelium directly. Dalmasso et al. (2008) used nanoparticle-encapsulated oral KPV in colitis models with 60–70% severity reduction. Standard oral KPV (without nanoparticles) shows comparable animal data for systemic absorption.
Can KPV help with skin conditions like eczema or psoriasis?
Preclinical evidence supports KPV for inflammatory skin conditions via MC1R-mediated NF-κB suppression in keratinocytes. Topical KPV formulations have been studied; subcutaneous injection provides systemic anti-inflammatory effects that may reduce skin flares. No published human RCTs exist for this indication.
How does KPV differ from full alpha-MSH?
Full α-MSH (13 amino acids) stimulates MC1R/MC3R for anti-inflammatory effects but also activates MC2R (ACTH receptor) and MC4R/MC5R, causing melanin production (skin darkening), appetite suppression, and cortisol effects. KPV's three amino acids selectively engage MC1R/MC3R anti-inflammatory signaling without these off-target effects.
Is there a risk of skin darkening with KPV?
No — unlike full α-MSH, KPV does not meaningfully activate MC1R-mediated melanogenesis. The tripeptide lacks the core melanocortin sequences responsible for tyrosinase activation. No skin darkening has been reported in KPV animal studies.
What is the optimal dosing frequency for KPV in an acute IBD flare?
For acute flares, twice-daily oral KPV (500 µg morning and evening) for the first 2–4 weeks, then once-daily maintenance, is a practical approach based on extrapolation from animal pharmacokinetics. KPV has a short half-life in plasma (<30 minutes), so twice-daily dosing maintains more consistent tissue exposure.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →